ZYME - Zymeworks Inc.
About Zymeworks Inc. (https://www.zymeworks.com)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | 1962 | $1,708,375 USD |
| Paul Moore | Chief Scientific Officer | 1968 | $998,368 USD |
| Bijal Desai | Senior Vice President of Finance | – | – |
| Diana Papove | Vice President of Corporate Communications | – | – |
| Kristin Stafford | Executive VP & CFO | 1983 | – |
| Laura O'Connor | Senior VP & Chief Human Resources Officer | – | – |
| Lindsey Foulkes | SVP of Corporate Development & Strategy | – | – |
| Mark Hollywood | Executive VP & Chief Operating Officer | 1969 | – |
| Sabeen Mekan | SVP & Chief Medical Officer | 1980 | – |
| Scott Platshon | Executive VP & Chief Business Officer | 1991 | – |
| Shrinal Inamdar | VP of Investor Relations | – | – |